SF Gate.com Home

SFGate Home
Today's Chronicle

Sports
Entertainment

News & Features
Business
Opinion
Politics
Technology
Crime
Science
Weird News
Polls
Photo Gallery
Columnists
Travel
Lottery
Obituaries

Personal Shopper

Classifieds
Jobs
Personals
Real Estate
Rentals
Vehicles
WebAds

Regional
Traffic
Weather
Live Views
Maps
Bay Area Traveler
Wine Country
Reno & Tahoe
Ski & Snow
Outdoors
Earthquakes
Schools

Entertainment
Food & Dining
Wine
Movies
Music & Nightlife
Events
Performance
Art
Books
Comics
TV & Radio
Search Listings

Living
Health
Home & Garden
Gay & Lesbian
Horoscope

Resources
Search & Archives
Feedback/Contacts
Corrections
Newsletters
Promotions
Site Index

Subscriber Service
Missed Delivery
Vacation Hold
Subscribe
Contact

Advertising
Advertise in Print
Place a Classified
Advertise Online
SF Gate Media Kit
 




House committee to investigate FDA's review of antidepressants and their possible link to suicide in children

LAURAN NEERGAARD, AP Medical Writer

Thursday, April 15, 2004

(04-15) 15:53 PDT WASHINGTON (AP) --

A House committee says it will investigate whether the Food and Drug Administration fully disclosed the disagreement among its scientists about whether antidepressants might be linked to suicide in children.

The FDA insists it is not clear whether the drugs have any link to suicidal behavior by children or teenagers, noting that depression itself can lead to suicide. An extensive agency investigation is under way; results are due this summer.

But at a Feb. 2 public meeting, FDA officials announced that some agency scientists believe a link already is proved, and presented the cases of possibly suicidal behavior.

At that meeting, the FDA's scientific advisers concluded that such a link has not be proved. They said that until the issue is settled, parents need to be warned that the drugs may cause agitation, anxiety and hostility among patients unusually vulnerable to rare side effects.

Critics complain that the FDA scientist who told his bosses he was convinced of a link, Dr. Andrew Mosholder, has been muzzled. Mosholder attended that February meeting but did not discuss his conclusion.

In a letter to Congress that was released Thursday, the FDA offered an explanation: While his boss presented Mosholder's data, top officials did not think Mosholder should argue the case was closed when that was not the agency's position.

"Having Dr. Mosholder present his conclusion to the advisory committee, with the appearance that it was an agency determination ... might lead patients who were actually benefiting from the use of these drugs to inappropriately discontinue therapy," the FDA wrote the House Energy and Commerce Committee.

The agency has urged caution in prescribing adult antidepressants for children. In addition, bowing to pressure from families, the agency warned last month that patients of any age should be monitored closely for signs of suicide when they first start antidepressants or change a dose.

But members of Congress question whether the FDA has gone far enough. Rep. Joe Barton, the House committee chairman, promised further investigation.

"There are troubling questions of whether FDA supervisors inappropriately suppressed significant information that would have been of consequence to their own advisory committee, not to mention the public," said Barton, R-Texas.

The FDA's drug chief, Dr. Robert Temple, said it is not unusual for agency scientists to disagree. He said the agency's advisers were given a clear picture of that disagreement and the data behind it.

"Nobody should think we're shrinking from this -- we raised it," he said.

"We don't want to scare people off drugs that may very well be useful. We don't want to exonerate drugs if they really are increasing the risk," Temple said. "We thought the investment of a few more months was worth it to get it right."

Last spring, the FDA spotted puzzling side-effect reports in studies of the use of the drug Paxil by children.

The FDA ordered details from the makers of Paxil and other antidepressants, reports that mentioned possibly suicidal behavior. That led the FDA to warn doctors to use caution when prescribing the drugs for minors while the agency assessed the risk.

British health authorities went much further, saying that because only one drug, Prozac, has been proven to alleviate pediatric depression, others are unsuitable for depressed youth.

graphical line

Buy The San Francisco Chronicle Get 50% off home delivery of the Chronicle for 12 weeks!
2004 Associated Press
 


Printer-friendly version
Email this article to a friend



Health
.Main Health Page

Bay Recruiter Top Jobs
RESTAURANT
Asst. GEN. MGR - PLUTO's seeks ambit

ACCOUNTANT
for Real Estate Co in SF. CPA/ RE/Mg

ACCOUNTING
Principals(R) ACCOUNTING Immediate O

HEALTHCARE
RN Case Managers Physical Therapists

PROPERTY
Mgmt - Apt Mgr. F/T job managing a 2

SALES
Music 4 Everyone needs Area Sales Mg

CLERICAL
Republic Indemnity, a leader in the

DRIVER
Interested in Becoming a Greyhound D

PSYCHIATRY
Openings Kaiser Permanente, re- nown

APPAREL
Koret, a women's sports- wear compan

TEACHERS
Garfield Charter School (K-8) is acc

PHARMACEUTICAL
Sales Manager

SECURITY
SUPERVISOR *$500 Hiring Bonus!* We o

REAL
ESTATE DIRECTOR OF ACQUISITIONS Grow

HOSPITALITY
SALES MANAGER Isn't it time to chang

About Top Jobs
View All Top Jobs